HER4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells

Molecular and Cellular Biology

Volumn 21, Issue 13, 2001, Pages 4265-4275

  Sartor, C I ^a   Zhou, H ^a   Kozlowska, E ^a   Guttridge, K ^a   Kawata, E ^a   Caskey, L ^a   Harrelson, J ^a   Hynes, N ^a   Ethier, S ^a   Calvo, B ^a   Earp III, H S ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMER; EPIDERMAL GROWTH FACTOR RECEPTOR; HEREGULIN 4; LIGAND; NEU DIFFERENTIATION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURFACE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL DIVISION; CELL SIZE; EPIDERMAL GROWTH FACTOR; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOBLOTTING; LIGANDS; NEUREGULIN-1; PHOSPHORYLATION; PHOSPHOTYROSINE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 0034967966     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.21.13.4265-4275.2001     Document Type: Article

References (56)

1. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: Implications for mammary tumors
2. A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells
3. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells
4. Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2
5. Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities
6. Involvement of the neuregulins and their receptors in cardiac and neural development
7. Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases
8. Ligands for ErbB-family receptors encoded by a neuregulin-like gene
9. An immunological approach reveals biological differences between the two NDF/heregulin receptors. ErbB-3 and ErbB-4
10. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
11. Characterization of a breast cancer cell differentiation factor that specifically activates the HER4/p180erbB4 receptor
12. Neu differentiation factor induces ErbB2 down-regulation and apoptosis of ErbB2-overexpressing breast tumor cells
13. Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research
14. Characterization of a naturally occurring ErbB4 isoform that does not bind or activate phosphatidyl inositol 3-kinase
15. Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation
16. Differential isolation of normal luminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media
17. Increased expression of c-erbB-2 in hormone-dependent breast cancer cells inhibits cell growth and induces differentiation
18. Defects in pathfinding by cranial neural crest cells in mice lacking the neuregulin receptor ErbB4
19. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling
20. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity
21. Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: A case-control study
22. Neuregulin-4: A novel growth factor that acts through the ErbB-4 receptor tyrosine kinase
23. Identification of heregulin, a specific activator of p185erbB2
24. ErbB4 signaling in the mammary gland is required for lobuloalveolar development and Stat5 activation during lactation
25. Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4
26. NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice
27. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness
28. Epidermal growth factor receptor family and chemosensitization
29. Improved retroviral vectors for gene transfer and expression
30. Use of sodium butyrate to enhance production of retroviral vectors expressing CFTR cDNA
31. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer
32. Production of high-titer helper-free retroviruses by transient transfection
33. Isolation of the neu/HER-2 stimulatory ligand: A 44 kd glycoprotein that induces differentiation of mammary tumor cells
34. Neu and its ligands: From an oncogene to neural factors
35. ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network
36. Heregulin induces tyrosine phosphorylation of HER4/p180erbB4
37. Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta
38. Activation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2
39. Specificity within the EGF family/ErbB receptor family signaling network
40. Modulation of membrane fluidity and lipidic metabolism in transformed rat fibroblasts induced by the sesquiterpenic hormone farnesylacetone
41. Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells
42. Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells
43. Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes
44. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
45. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor
46. Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 alpha, neuregulin-1 beta, and betacellulin, in normal endometrium and endometrial cancer
47. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers
48. Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo
49. ErbB-4 ribozymes abolish neuregulin-induced mitogenesis
50. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor
51. Cadherins and tissue formation: Integrating adhesion and signaling
52. ErbB2 expression increases the spectrum and potency of ligand-mediated signal transduction through ErbB4
53. Alternative intracellular routing of ErbB receptors may determine signaling potency
54. Neu differentiation factor: A transmembrane glycoprotein containing an EGF domain and an immunoglobulin homology unit
55. Changes in heregulin beta1 (HRG-beta1) signaling after inhibition of ErbB-2 expression in a human breast cancer cell line
56. Neuregulin-3 (NRG3): A novel neural tissue-enriched protein that binds and activates ErbB4